FDA clears IND for Phase 2 study of VT-7208 in CSU
Processa Pharmaceuticals announced FDA clearance for a VT-7208 CSU Phase 2 trial and appointed Dr. Sheila Gujrathi as Executive Chair, supported by a $200M investment.
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Processa Pharmaceuticals announced FDA clearance for a VT-7208 CSU Phase 2 trial and appointed Dr. Sheila Gujrathi as Executive Chair, supported by a $200M investment.
Azitra adjusted the protocol of its topical ATR-04-484 Phase 1/2 study to include patients treating rash caused by KRAS and MEK inhibitors, widening the potential patient pool beyo…
Valion Bio showed no toxicity in a government-funded Entolimod study. This safety data de-risks the drug development and supports moving toward a planned efficacy trial.
Bicycle Therapeutics announced that nuzefatide pevedotin received FDA Orphan Drug Designation for pancreatic cancer, ahead of expected phase 2 trial updates and the anticipated ini…
Synaptics Incorporated filed an amended and restated 2019 Equity and Incentive Compensation Plan to attract and retain employees. This regulatory filing is relevant as it outlines …
The Federal Reserve issues a statement regarding the FOMC meeting.
DBV Technologies reported Q3 2026 financials and submitted a BLA for the VIASKIN Peanut Patch in children aged 4-7 years, while maintaining cash through Q3 2027.
Geron halted the Phase 3 IMpactMF trial of imetelstat in JAK inhibitor relapsed/refractory myelofibrosis following Data Monitoring Committee advice, although the company remains co…
Matternet filed amended and restated bylaws with the SEC, as outlined in an Exhibit 3.1 filing. Corporate governance changes like this generally signal internal structure adjustmen…
The panel has given the company an extension to remain listed on The Nasdaq Capital Market, contingent on final compliance with listing criteria by February 16, 2027.
The company filed an Amended and Restated Declaration of Trust under Maryland law. This legal update is relevant as it formalizes the trust's structure and purpose.
Following a Nasdaq panel decision to delist, OSR Health remains focused on regaining compliance by November 6. The company confirmed its VXM01 funding mechanism and commitment to e…
Benitec Biopharma announced 100% responder rates for high and low dose BB-301; interim high dose results showed superior improvements in swallowing function needed to advance towar…
Palvella Therapeutics announced FDA acceptance and Priority Review for its rapamycin NDA, with a PDUFA date set for February 2027. The breakthrough therapy designation and strong P…
Cardiff Oncology amended its certificate of incorporation on Oct. 22, 2026, increasing the number of authorized common shares to 300 million. This authorization supports future sha…
Madison Square Garden Sports Corp. filed to restate its articles of incorporation adhering to Nevada state statutory requirements.
Rekor Systems received a six-month extension to regain Nasdaq's $1.00 minimum bid price requirement.
Oncolytics Biotech's updated Phase 1/2 study shows a 15-month median duration of response for pelareorep combined with an immuno-oncology therapy in anal cancer, surpassing the cur…
The company filed its Form 10-Q to cure a listing violation due to the delay of the third quarter reporting period.
aTyr Pharma filed an amendment to its certificate of incorporation as part of a reverse stock split effective in roughly two years, which consolidates 40 shares of common stock int…